Become A Featured Company

New York Moves Closer to Legalizing Adult-Use, Game Changer for Cannabis Industry

Robin Lefferts

July 31st, 2018

Exclusive, News, Top Story

New York is about to be surrounded by legal weed. Medical marijuana has been legal in the Northeast and Canada for some time now, but Massachusetts and Vermont have now legalized adult use, and momentum is building in New Jersey as Gov. Phil Murphy makes good on a top campaign promise. Canada kicks off its adult-use program in October.

“For all intents and purposes it is going to be here anyway,” New York Gov. Andrew Cuomo admitted as much to the New York Post in April.

And now, the New York Department of Health, which oversees the state’s medical marijuana program, has essentially endorsed adult-use legalization in a recent 75-page report commissioned by Cuomo himself.

“The positive effects of a regulated marijuana market in NYS outweigh the potential negative impacts,” the report concludes. “It has become less a question of whether to legalize but how to do so responsibly.”

Legalization is also a hot topic of discussion as the state moves to the November elections, and there is broad support for legalized adult-use among the top candidates. Pot could soon be legal in the Big Apple and that would be a game-changer.

The New York Market

The Department of Health’s report estimates there are about 1.3 million marijuana users in the state and that adult-use could reach US$3.5 billion in annual sales, about 16 times greater than today’s medical marijuana market and on par with California’s current retail sales estimates. California is the world’s largest legal cannabis market.

Aside from sheer market size, New York would further legitimize this fast-evolving industry. Adult-use is already legal on the entire West Coast, further legalization on the Northeast of the country, a center of politics, commerce and culture, would give the industry another big push toward the mainstream, bringing more customers and investment capital.

There are only 10 cannabis license holders in the state’s current medical cannabis program. Each licensee is allowed to operate a cultivation and manufacturing facility and four stores to sell its products. When the state legalizes adult-use, these licensees would meaningfully benefit from existing infrastructure and first mover advantage. They are also likely to be some of the first to receive adult-use licenses given they have already been operating under the scrutiny of the state for years.

New York state’s medical marijuana program has been growing steadily and now has about 60,000 active patients.  The state has expanded access by gradually increasing the list of qualifying medical conditions and variety of products allowed. Most recently, the state added opioid use as a qualifying condition, offering cannabis as a substitute.  Arcview Market Research forecasts medical sales in the state will total US$219 million this year.

MedMen’s Position

MedMen 5th Avenue

Among the 10 medical marijuana license holders in the state is MedMen Enterprises Inc. (CSE: MMEN) (OTCQB: MMNFF) with a flagship store on Manhattan’s 5th Avenue.  In sharp contrast to the other license holders in the state whose message and brands are very medical in nature, MedMen has been outwardly courting general cannabis consumers. The brand is already synonymous with cannabis retail with its shops being called the “Apple Store of Weed.” MedMen’s consumer brand appeals to medical marijuana patients as well. Its Manhattan store, one of only three allowed in the borough, is the company’s best performing in New York state.

While the New York Department of Health report recommended that the state limit the number of licenses initially available, even if the number of licenses doubles to 20 and the number of stores each is allowed to open doubles to eight, there would be 160 stores in the state.  At US$3.5 billion in annual sales, this would represent an average of US$22 million in revenue per store – consistent with the run rate of MedMen’s more mature stores in California.  MedMen should outperform in New York, given the brand equity it has already built with cannabis consumers. Even at average market share and applying a 5x multiple to its New York operations alone, it would result in an enterprise value of US$775 million. That would account for about half of MedMen’s current enterprise value, not including the 41 stores outside New York state the company plans on opening by 2020. The company already has eight stores in California and two in Nevada and has a license to open 25 stores in Florida.

The foresight MedMen had to acquire one of only five medical marijuana licenses in New York in early 2017 seems poised to pay off handsomely. The report from the Department of Health cites other positive benefits of legalization including improved quality control and consumer protection, potentially significant tax revenue and job creation, and the potential to reduce opioid prescriptions and deaths, as well as addressing social justice concerns.

Disclaimer  

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Robin Lefferts

Robin Lefferts has been involved in the legal cannabis industry since 2012, sometimes as an active participant and always as an interested observer.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading